Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Sera Prognostics ( (SERA) ) has provided an announcement.
On January 6, 2025, a study abstract published by the Society for Maternal Fetal Medicine highlighted the results of the Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal Outcomes (PRIME) study. These findings will be further detailed at the SMFM 2025 Pregnancy Meeting and discussed by Sera Prognostics through a conference call on February 6, 2025, indicating the company’s engagement in advancing maternal and fetal health research.
More about Sera Prognostics
YTD Price Performance: -7.56%
Average Trading Volume: 92,941
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $260M
For a thorough assessment of SERA stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Walmart (NYSE:WMT) Hits Mar-a-Lago to Talk Tariffs
- Ford (NYSE:F) Finds Battery Troubles at Every Turn
- Intel (NASDAQ:INTC) Makes Appearances in More Laptops, Cars
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
